IBDEI3IX ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,2308,0)
 ;;=RADIATION^19^206
 ;;^UTILITY(U,$J,358.4,2309,0)
 ;;=OCCUPATIONAL^15^206
 ;;^UTILITY(U,$J,358.4,2310,0)
 ;;=PAIN^16^206
 ;;^UTILITY(U,$J,358.4,2311,0)
 ;;=PLEURAL DISEASE^17^206
 ;;^UTILITY(U,$J,358.4,2312,0)
 ;;=PSYCHIATRIC/BEHAVIORAL^18^206
 ;;^UTILITY(U,$J,358.4,2313,0)
 ;;=SKIN^22^206
 ;;^UTILITY(U,$J,358.4,2314,0)
 ;;=NEUROLOGIC^12^206
 ;;^UTILITY(U,$J,358.4,2315,0)
 ;;=OBSTRUCTIVE DISEASE^14^206
 ;;^UTILITY(U,$J,358.4,2316,0)
 ;;=VASCULAR^24^206
 ;;^UTILITY(U,$J,358.4,2317,0)
 ;;=SYMPTOMS^21^206
 ;;^UTILITY(U,$J,358.4,2318,0)
 ;;=FOLLOW-UP^2^207
 ;;^UTILITY(U,$J,358.4,2319,0)
 ;;=CONSULTATIONS^1^207
 ;;^UTILITY(U,$J,358.4,2320,0)
 ;;=NURSING^4^207
 ;;^UTILITY(U,$J,358.4,2321,0)
 ;;=NEW PATIENT^3^207
 ;;^UTILITY(U,$J,358.4,2322,0)
 ;;=TREATMENT PLANNING^12^208
 ;;^UTILITY(U,$J,358.4,2323,0)
 ;;=SIMULATION^7^208
 ;;^UTILITY(U,$J,358.4,2324,0)
 ;;=TREATMENT DEVICES^11^208
 ;;^UTILITY(U,$J,358.4,2325,0)
 ;;=DOSIMETRY CALCULATIONS^2^208
 ;;^UTILITY(U,$J,358.4,2326,0)
 ;;=TELETHERAPY ISODOSE PLAN^9^208
 ;;^UTILITY(U,$J,358.4,2327,0)
 ;;=WEEKLY TX MANAGEMENT^13^208
 ;;^UTILITY(U,$J,358.4,2328,0)
 ;;=MISCELLANEOUS^6^208
 ;;^UTILITY(U,$J,358.4,2329,0)
 ;;=IMRT PLAN^4^208
 ;;^UTILITY(U,$J,358.4,2330,0)
 ;;=TREATMENT DELIVERY^10^208
 ;;^UTILITY(U,$J,358.4,2331,0)
 ;;=BRACHYTHERAPY ISODOSE PLAN^1^208
 ;;^UTILITY(U,$J,358.4,2332,0)
 ;;=STEREOTACTIC TREATMENT^8^208
 ;;^UTILITY(U,$J,358.4,2333,0)
 ;;=GUIDANCE^3^208
 ;;^UTILITY(U,$J,358.4,2334,0)
 ;;=LARYNGOSCOPY^5^208
 ;;^UTILITY(U,$J,358.4,2335,0)
 ;;=RADIATION TREATMENT^1^209
 ;;^UTILITY(U,$J,358.4,2336,0)
 ;;=RADIATION FOLLOW-UP^2^209
 ;;^UTILITY(U,$J,358.4,2337,0)
 ;;=BENIGN NEOPLASMS^4^209
 ;;^UTILITY(U,$J,358.4,2338,0)
 ;;=URINARY TRACT^43^209
 ;;^UTILITY(U,$J,358.4,2339,0)
 ;;=BREAST-FEMALE^7^209
 ;;^UTILITY(U,$J,358.4,2340,0)
 ;;=EYE/BRAIN/CNS^14^209
 ;;^UTILITY(U,$J,358.4,2341,0)
 ;;=CONNECTIVE & SOFT TISSUE^11^209
 ;;^UTILITY(U,$J,358.4,2342,0)
 ;;=ESOPHAGUS^13^209
 ;;^UTILITY(U,$J,358.4,2343,0)
 ;;=HYPOPHARYNX^18^209
 ;;^UTILITY(U,$J,358.4,2344,0)
 ;;=LARYNX^19^209
 ;;^UTILITY(U,$J,358.4,2345,0)
 ;;=BRONCHUS/LUNG^9^209
 ;;^UTILITY(U,$J,358.4,2346,0)
 ;;=LYMPHOID/HEMATOPOIETIC^22^209
 ;;^UTILITY(U,$J,358.4,2347,0)
 ;;=MELANOMA^23^209
 ;;^UTILITY(U,$J,358.4,2348,0)
 ;;=MOUTH^27^209
 ;;^UTILITY(U,$J,358.4,2349,0)
 ;;=NASOPHARYNX^28^209
 ;;^UTILITY(U,$J,358.4,2350,0)
 ;;=OROPHARYNX^29^209
 ;;^UTILITY(U,$J,358.4,2351,0)
 ;;=PANCREAS^31^209
 ;;^UTILITY(U,$J,358.4,2352,0)
 ;;=ANUS/ANAL CANAL^3^209
 ;;^UTILITY(U,$J,358.4,2353,0)
 ;;=SALIVARY GLANDS^35^209
 ;;^UTILITY(U,$J,358.4,2354,0)
 ;;=SECONDARY MALIG NEOP-OTH SITES^38^209
 ;;^UTILITY(U,$J,358.4,2355,0)
 ;;=LIP/ORAL CAVITY/PHARYNX^20^209
 ;;^UTILITY(U,$J,358.4,2356,0)
 ;;=MISCELLANEOUS^26^209
 ;;^UTILITY(U,$J,358.4,2357,0)
 ;;=PERSONAL HX OF CANCER^32^209
 ;;^UTILITY(U,$J,358.4,2358,0)
 ;;=MERKEL CELL CARCINOMA^24^209
 ;;^UTILITY(U,$J,358.4,2359,0)
 ;;=COLON^10^209
 ;;^UTILITY(U,$J,358.4,2360,0)
 ;;=BREAST-MALE^8^209
 ;;^UTILITY(U,$J,358.4,2361,0)
 ;;=GENITAL ORGANS-MALE^16^209
 ;;^UTILITY(U,$J,358.4,2362,0)
 ;;=GENITAL ORGANS-FEMALE^15^209
 ;;^UTILITY(U,$J,358.4,2363,0)
 ;;=PALATE^30^209
 ;;^UTILITY(U,$J,358.4,2364,0)
 ;;=STOMACH^41^209
 ;;^UTILITY(U,$J,358.4,2365,0)
 ;;=SMALL INTESTINE^40^209
 ;;^UTILITY(U,$J,358.4,2366,0)
 ;;=LIVER/INTRAHEPATIC BILE DUCTS^21^209
 ;;^UTILITY(U,$J,358.4,2367,0)
 ;;=BILIARY TRACT^5^209
 ;;^UTILITY(U,$J,358.4,2368,0)
 ;;=DIGESTIVE ORGAN^12^209
 ;;^UTILITY(U,$J,358.4,2369,0)
 ;;=RESPIRATORY/INTRATHORACIC ORGANS^33^209
 ;;^UTILITY(U,$J,358.4,2370,0)
 ;;=HEART/MEDIASTINUM/PLEURA^17^209
